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Aortic aneurysms in Loeys-Dietz syndrome —  
a tale of two pathways?
Frank Davis, Debra L. Rateri, and Alan Daugherty
Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, USA.
Loeys-Dietz syndrome (LDS) is a connective tissue disorder that is char-
acterized by skeletal abnormalities, craniofacial malformations, and a 
high predisposition for aortic aneurysm. In this issue of the JCI, Gallo et 
al. developed transgenic mouse strains harboring missense mutations in 
the genes encoding type I or II TGF-β receptors. These mice exhibited sev-
eral LDS-associated phenotypes. Despite being functionally defective, the 
mutated receptors enhanced TGF-β signaling in vivo, inferred by detection 
of increased levels of phosphorylated Smad2. Aortic aneurysms in these 
LDS mice were ablated by treatment with the Ang II type 1 (AT1) receptor 
antagonist losartan. The results from this study will foster further interest 
into the potential therapeutic implications of AT1 receptor antagonists.
TGF-β and Ang II pathways in 
thoracic aortic aneurysmal formation
Aneurysms that present in the thoracic 
aorta have a wide range of syndromic and 
nonsyndromic associations (1). Marfan 
syndrome is one of the most researched 
syndromic associations and is attributed to 
a wide spectrum of mutations in fibrillin-1, 
which have been proposed to enhance the 
bioavailability of TGF-β (2). The under-
standing of the role of TGF-β in the etiol-
ogy of thoracic aortic aneurysms (TAAs) 
moved forward with the development of 
mice that expressed the C1039G mutant of 
fibrillin-1. These mice, colloquially referred 
to the “Marfan mouse,” exhibit many 
Marfan-associated phenotypes, including 
a predisposition for aortic aneurysms. 
TGF-β–neutralizing antibody administra-
tion to Marfan mice prevented the charac-
teristic media elastin disruption and aor-
tic root expansion (3). Furthermore, the 
neutralizing antibody decreased canonical 
TGF-β signaling in aortic smooth muscle 
cells, as defined by immunostaining of tis-
sues for the phosphorylated form of Smad2 
(pSmad2). Another seminal discovery in 
the Marfan mouse was that administration 
of losartan, the initial member of the Ang 
II type 1 receptor (AT1R) blocker (ARB) 
class, ablated ascending aortic dilation. 
Subsequent studies in this mouse model 
have demonstrated that losartan-associ-
ated reductions in ascending aortic expan-
sion are attributable to inhibition of the 
ERK pathway (4, 5). These groundbreak-
ing studies in mice have assisted in devel-
opment of multiple clinical trials that are 
evaluating efficacy of AT1R antagonism 
in thoracic aortic dilation of patients with 
Marfan syndrome (6). Although these stud-
ies shed light on the interactions between 
TGF-β and AT1R signaling in TAA devel-
opment, the specific mechanism of these 
interactions has not been elucidated (7).
TGF-β was further implicated in the 
development of aortic aneurysms fol-
lowing the discovery of mutations in the 
genes encoding TGF-β receptors in indi-
viduals afflicted with a clinical syndrome 
that has similarities to Marfan syndrome. 
This condition was subsequently termed 
Loeys-Dietz syndrome (LDS). Patients 
afflicted with LDS have a more aggressive 
form of ascending aortic dilation com-
pared with those with Marfan syndrome 
(8). Dilation of the aortic root is detected 
very early, with documented aortic dis-
sections occurring in patients with LDS 
as young as 3 months of age (9). Unlike 
Marfan syndrome, the vascular patholo-
gies associated with LDS are more diffuse 
in location, as these aneurysms occur in 
other aortic regions and several vascular 
beds (10). The genetic basis of LDS is the 
presence of mutations in the genes encod-
ing either type I or type II TGF-β receptors 
(11). TGF-β receptors function as multi-
mers of both subtypes; therefore, clinical 
presentations are similar when defects 
are present in either receptor subtype. 
Although the TGF-β receptor mutations 
result in impaired function, detection of 
enhanced Smad2 or Smad3 phosphoryla-
tion in surgical samples implies that TGF-β 
signaling is actually increased in patients 
with LDS (11). The involvement of TGF-β 
signaling in LDS development parallels the 
mechanisms of TAAs in Marfan syndrome. 
Unlike Marfan syndrome, there is a paucity 
of information on a role for Ang II in LDS.
TGF-β receptor mutations promote 
aortic aneurysms in LDS  
mouse models
In this issue of the JCI, Gallo et al. (12) 
generated an array of mouse models with 
TGF-β receptor dysfunction. These mouse 
models included mice with haploinsuffi-
ciency of either TGF-β receptor (Tgfbr1+/– 
or Tgfbr2+/– mice), knockin of LDS-asso-
ciated alleles (Tgfbr1M318R or Tgfbr2G357W 
mice), and transgenic overexpression of 
the Tgfbr2G357W mutant. Haploinsuffi-
ciency of either receptor subtype did not 
produce vascular pathologies; however, 
heterogenous knockin of Tgfbr1M318R or 
Tgfbr2G357W mutations or transgenic over-
expression of mutated Tgfbr2G357W led to 
severe aortic pathologies. These included 
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aortic root expansion and rupture and 
increased tortuosity of the thoracic aorta. 
Overall, mice expressing mutant forms of 
TGF-β receptors exhibited many features 
of LDS, which permitted mechanistic 
studies of this disease.
Initially, mechanistic insight was gleaned 
from cultured smooth muscle cells har-
vested from aortic roots of wild-type, 
Tgfbr2+/–, Tgfbr2G357W knockin, and trans-
genic mice. As expected, stimulation with 
TGF-β promoted less pSmad2 abundance 
in cells expressing mutant receptors com-
pared with controls. The lack of TGF-β 
responsiveness was not attributable to 
differences in cell surface expression of 
the receptors. Vascular smooth muscle 
cells harvested from patients with LDS 
also demonstrated partial attenuation 
of TGF-β–induced Smad2 phosphoryla-
tion. Receptor deficiencies did not lead to 
marked upregulation of TGF-β secretion 
in mouse cells, and only TGF-β2 secretion 
was increased in cells from patients with 
LDS. The results from these cell culture 
experiments corroborated previous studies 
that demonstrated decreased TGF-β sig-
naling as a result of LDS-associated TGF-β 
receptor mutations (1).
Subsequent studies by Gallo et al. deter-
mined the fidelity of extrapolating these 
cell culture studies to the intact mouse (12). 
Western blot analysis of aortic root tissue 
from mice harboring either the Tgfbr1M318R 
or Tgfbr2G357W mutation revealed that there 
was no alteration in pSmad2 abundance 
within the 24-week interval in which aortic 
expansion was measured. Given that anal-
ysis of whole tissue homogenates might 
obfuscate regional pSmad2 changes, Gallo 
et al. (12) performed immunostaining to 
visualize pSmad2 in aortic roots. While this 
technique does not easily lend itself to quan-
titative comparisons, greater immunofluo-
rescent signals were observed in aortic media 
and adventitial tissues from Tgfbr2G357W 
knockin mice compared with controls. The 
explanation as to why these data seemingly 
contradict the cell culture studies is cer-
tainly a matter of debate and intrigue. One 
potential issue is the promiscuity of Smad2 
phosphorylation, which is not exclusively a 
result of TGF-β signaling. Therefore, the use 
of Smad2 phosphorylation as an indicator 
of TGF-β pathway activation could com-
promise data interpretation (13). Another 
intriguing aspect of the Gallo et al. study 
was that administration of a TGF-β–neutral-
izing antibody failed to prevent aortic root 
dilation, unlike the efficacy of this antibody 
treatment that has been demonstrated in the 
Marfan mouse (3).
In contrast to TGF-β neutralization, 
Gallo et al. (12) provided convincing 
evidence that losartan administration 
ablated aortic pathology and expan-
sion. Similar to the Marfan mouse, the 
decreased pathology was not mimicked 
by administration of a β-adrenoceptor 
antagonist (3). While losartan is primarily 
defined as an AT1R antagonist, its metab-
olites do have a potential range of other 
activities (14). Therefore, evaluation of 
other ARBs would assist in determining 
whether losartan-associated effects are 
due specifically to AT1R antagonism.
Mechanism of TGF-β and Ang II 
interactions in TAA development
The authors conclude that aortic pathol-
ogies are generated by Ang II augmenta-
tion of TGF-β signaling (Figure 1). Indeed, 
Ang II stimulates TGF-β signaling by 
promoting secretion of TGF-β isoforms 
from vascular smooth muscle cells (15). 
Conversely, TGF-β signaling in vascular 
smooth muscle cells downregulates AT1R 
expression (16). The specific mechanisms 
by which defective TGF-β receptors lead 
to augmented AT1R stimulation and gen-
eration of aortic pathologies in LDS is 
still a quandary. This issue is further com-
plicated by evidence that suggests that 
TGF-β promotes ascending aortic dila-
tion through a combination of AT1R-de-
pendent and -independent pathways (17). 
Clearly, additional studies are warranted 
to further elucidate the pathways that 
promote aortic aneurysm.
Therapeutic implications
Overall, the findings of Gallo et al. (12) 
provide important insight into the patho-
genesis of aortic aneurysms in LDS. The 
authors demonstrated that a missense 
mutation in a single allele within either of 
the genes encoding TGF-β receptor type 1 
or 2 is sufficient to recapitulate LDS phe-
notypes in mice. In addition, these stud-
ies provide rationale for considering the 
Figure 1
Convergence of the TGF-β and Ang II signaling pathways is implicated in TAA. Missense muta-
tions in either the TGF-β receptor (TGFR) type 1 or 2 subtypes, specifically Tgfbr2G357W and 
Tgfbr1M318R, lead to increased abundance of pSmad2 and pERK in mouse models of LDS. The 
increase in these activated proteins correlates with increased elastin fragmentation and aortic 
root dilation. Administration of losartan, an ARB, suppressed Smad2 and ERK phosphorylation 
and prevented aortic dilation. However, important mechanistic questions remain. (i) Why does 
administration of a TGF-β–neutralizing antibody (1D11 Nab) fail to reduce aortic root dilation? 
(ii) How does defective TGF-β signaling augment AT1R stimulation? (iii) How do functionally 
defective TGF-β receptors promote increased phosphorylation of Smad2 and ERK? (iv) What 
are the downstream targets of pSmad2 and pERK that cause elastin fragmentation and subse-
quent aortic aneurysm?
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application of AT1R antagonism as a ther-
apy for patients with LDS. There is both 
retrospective and evolving prospective evi-
dence that AT1R antagonism may be bene-
ficial to patients with Marfan syndrome (6, 
18, 19). Together, the findings in patients 
with Marfan syndrome and the results 
from the Gallo et al. study (12) indicate 
that patients with LDS may potentially 
benefit from AT1R antagonism. Losartan 
has been the ARB of choice in most ongo-
ing trials; however, the use of an ARB with 
a more favorable pharmacokinetic profile 
and longer half-life may enhance the pro-
tective effects against TAAs. The availabil-
ity of the LDS mouse described by Gallo 
et al. (12) provides a model to determine 
the relative efficacies of this class of drugs 
before application to humans.
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Aniridia is a panocular disorder that severely affects vision in early life. Most 
cases are caused by dominantly inherited mutations or deletions of the PAX6 
gene, which encodes a transcription factor that is essential for the develop-
ment of the eye and the central nervous system. In this issue of the JCI, Gre-
gory-Evans and colleagues demonstrate that early postnatal topical adminis-
tration of an ataluren-based formulation reverses congenital malformations 
in the postnatal mouse eye, providing evidence that manipulation of PAX6 
after birth may lead to corrective tissue remodeling. These findings offer 
hope that ataluren administration could be a therapeutic paradigm applica-
ble to some major congenital eye defects.
Mutations that inactivate gene function by 
promoting premature translational termi-
nation cause a large number of human dis-
eases. It is thought that at least one-third of 
all genetic diseases and many types of can-
cer are the result of such mutations (1, 2). 
These mutations are referred to as nonsense 
mutations, premature stop mutations, or 
premature termination codons (PTCs). 
Given that PTCs often result in a complete 
loss of protein function, the associated 
diseases usually manifest as severe pheno-
types. Examples of PTC-associated diseases 
include CF, Duchenne muscular dystrophy 
(DMD), and aniridia, among others.
Aniridia, a panocular disorder
Aniridia is a rare eye disease with an esti-
mated prevalence of approximately 1 in 
40,000 to 1 in 100,000 individuals. It is 
present at birth and characterized by a total 
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